63909-57-9

Basic information

• Product Name: Phosphonic acid, [(3-fluorophenyl)methyl]-, diethyl ester
• CAS NO: 63909-57-9
• Molecular Formula: C11H16FO3P
• Molecular Weight: 246.218
• Mol File: 63909-57-9.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Phosphonic acid, [(3-fluorophenyl)methyl]-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonic acid, [(3-fluorophenyl)methyl]-, diethyl ester(63909-57-9)
• EPA Substance Registry System: Phosphonic acid, [(3-fluorophenyl)methyl]-, diethyl ester(63909-57-9)

Safety Data

• Hazardous Substances Data: 63909-57-9(Hazardous Substances Data)

Upstream product

• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 122-52-1 triethyl phosphite 
• 456-42-8 m-fluorobenzyl chloride 

Downstream Products

• 193203-93-9 1-benzyl-4-(3-fluorobenzylidene)piperidine 
• 1258962-79-6 (E)-4-(3-fluorostyryl)-N,N-dimethylaniline 
• 1412978-66-5 benzyl 4-(3-fluorobenzylidene)piperidine-1-carboxylate 
• 177981-30-5 trans-3,3'-difluoro-1,2-diphenylethylene 
• 1624610-63-4 (E)-2-(3-fluorostyryl)pyridine 

Relevant articles and documents

A new insight into the push-pull effect of substituents via the stilbene-like model compounds

In this paper, authors report on 1-pyridyl-2-arylethenes, 1-furyl-2-arylethylenes, 1,2-diphenylpropylenes and substituted cinnamyl anilines as stilbene-like model compounds to investigate the factors dominating the push-pull effect of substituents via usi

The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, th

TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against me